Pediatric antifungal agents
- 1 December 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Infectious Diseases
- Vol. 22 (6), 553-558
- https://doi.org/10.1097/qco.0b013e3283321ccc
Abstract
In immunocompromised hosts, invasive fungal infections are common and fatal. In the past decade, the antifungal armamentarium against invasive mycoses has expanded greatly. The purpose of the present report is to review the most recent literature addressing the use of antifungal agents in children. Most studies evaluating the safety and efficacy of antifungal agents are limited to adults. However, important progress has been made in describing the pharmacokinetics and safety of newer antifungal agents in children, including the echinocandins. Dosage guidelines for newer antifungal agents are currently based on adult and limited pediatric data. Because important developmental pharmacology changes occur throughout childhood impacting the pharmacokinetics of these agents, antifungal studies specifically designed for children are necessary.Keywords
This publication has 62 references indexed in Scilit:
- Pharmacokinetics of an Elevated Dosage of Micafungin in Premature NeonatesThe Pediatric Infectious Disease Journal, 2009
- Pharmacokinetics and Safety of Caspofungin in Older Infants and ToddlersAntimicrobial Agents and Chemotherapy, 2009
- Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of AgeAntimicrobial Agents and Chemotherapy, 2009
- Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric StudiesAntimicrobial Agents and Chemotherapy, 2009
- Population Pharmacokinetics of Fluconazole in Young InfantsAntimicrobial Agents and Chemotherapy, 2008
- First, Do No HarmPEDIATRICS, 2008
- The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental HematogenousCandidaMeningoencephalitis: Implications for Echinocandin Therapy in NeonatesThe Journal of Infectious Diseases, 2008
- Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal DosingAntimicrobial Agents and Chemotherapy, 2007
- Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patientsBMC Infectious Diseases, 2007
- Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonatesThe Journal of Pediatrics, 1990